304 related articles for article (PubMed ID: 15032719)
1. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.
Tiseo M; Loprevite M; Ardizzoni A
Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):139-48. PubMed ID: 15032719
[TBL] [Abstract][Full Text] [Related]
2. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
3. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy.
Janmaat ML; Giaccone G
Drugs Today (Barc); 2003; 39 Suppl C():61-80. PubMed ID: 14988746
[TBL] [Abstract][Full Text] [Related]
4. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
Blackledge G; Averbuch S
Br J Cancer; 2004 Feb; 90(3):566-72. PubMed ID: 14760365
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.
Ciardiello F; De Vita F; Orditura M; De Placido S; Tortora G
Expert Opin Emerg Drugs; 2003 Nov; 8(2):501-14. PubMed ID: 14662002
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
[TBL] [Abstract][Full Text] [Related]
8. The role of EGFR inhibitors in nonsmall cell lung cancer.
Ciardiello F; De Vita F; Orditura M; Tortora G
Curr Opin Oncol; 2004 Mar; 16(2):130-5. PubMed ID: 15075904
[TBL] [Abstract][Full Text] [Related]
9. The ErbB receptor family: a therapeutic target for cancer.
de Bono JS; Rowinsky EK
Trends Mol Med; 2002; 8(4 Suppl):S19-26. PubMed ID: 11927283
[TBL] [Abstract][Full Text] [Related]
10. Targeting epidermal growth factor receptor in lung cancer.
Baselga J; Albanell J
Curr Oncol Rep; 2002 Jul; 4(4):317-24. PubMed ID: 12044241
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
Thomas M
Cancer Nurs; 2003 Dec; 26(6 Suppl):21S-25S. PubMed ID: 15025409
[TBL] [Abstract][Full Text] [Related]
13. Targeting the EGFR pathway for cancer therapy.
Johnston JB; Navaratnam S; Pitz MW; Maniate JM; Wiechec E; Baust H; Gingerich J; Skliris GP; Murphy LC; Los M
Curr Med Chem; 2006; 13(29):3483-92. PubMed ID: 17168718
[TBL] [Abstract][Full Text] [Related]
14. [Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors].
Tamura T
Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):233-6. PubMed ID: 11904986
[TBL] [Abstract][Full Text] [Related]
15. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
Herbst RS
Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
[TBL] [Abstract][Full Text] [Related]
16. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status.
Suzuki T; Nakagawa T; Endo H; Mitsudomi T; Masuda A; Yatabe Y; Sugiura T; Takahashi T; Hida T
Lung Cancer; 2003 Oct; 42(1):35-41. PubMed ID: 14512185
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor biology (IMC-C225).
Kim ES; Khuri FR; Herbst RS
Curr Opin Oncol; 2001 Nov; 13(6):506-13. PubMed ID: 11673692
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
Langer CJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
[TBL] [Abstract][Full Text] [Related]
19. Growth factors and their receptors: new targets for prostate cancer therapy.
Barton J; Blackledge G; Wakeling A
Urology; 2001 Aug; 58(2 Suppl 1):114-22. PubMed ID: 11502465
[TBL] [Abstract][Full Text] [Related]
20. Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer.
Nakamura H; Takamori S; Fujii T; Ono M; Yamana H; Kuwano M; Shirouzu K
Cancer Lett; 2005 Dec; 230(1):33-46. PubMed ID: 16253759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]